Funded Grants

One of the most important advances in our understanding of chronic pain over the last decade or so is the realization that neurons are not the only cells in the central nervous system participating in the processing of pain signals.

Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for patients with depression who have not responded to antidepressant medications.

Dr. David and his research team are studying the mechanisms that control the delivery and release of iron in the nervous system.

The purpose of this project is to develop promoters. Promoters are pieces of DNA, which act as switches to turn genes on and off.

The blood-brain barrier (BBB) plays an essential role in protecting the brain from blood-borne diseases.

The team wants to take a new breakthrough technology called Cyto-iGluSnFR (pronounced “sight-oh-eye-glue-sniffer”) and adapt it for the discovery of drugs to treat a variety of brain and eye diseases.

No medications exist that can stop or even slow the progression for Alzheimer Disease (AD).

Two diseases that show very different trajectories have nevertheless led researchers to identify dysfunction in a common brain network.

Recent estimates indicate that 1 in 5 Canadians are affected annually by mood, anxiety and other mental illnesses.

Autism spectrum disorders are neurodevelopmental disorders characterized by deficits in social interaction, poor communication, and restricted, stereotyped patterns of behavior.